Cargando…

Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma

Urothelial cancer (UC) is one of the common refractory tumors and chemotherapy is the primary treatment for it. The advent of immune checkpoint inhibitors (ICI) has facilitated the development of treatment strategies for UC patients. To screen out UC patients sensitive to ICI, researchers have propo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yueming, Li, Xuechun, Zhou, Rui, Lin, Anqi, Cao, Manming, Lyu, Qingwen, Luo, Peng, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424112/ https://www.ncbi.nlm.nih.gov/pubmed/34512351 http://dx.doi.org/10.3389/fphar.2021.723066

Ejemplares similares

Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma
por: Hong, Shuo, et al.
Publicado: (2021)

Activation of the DDR Pathway Leads to the Down-Regulation of the TGFβ Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma
por: Zhou, Chaozheng, et al.
Publicado: (2021)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
por: Lyu, Qiong, et al.
Publicado: (2020)

Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration
por: Guan, Rui, et al.
Publicado: (2021)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
por: Qu, Hong-Chen, et al.
Publicado: (2020)

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
por: Yi, Ruibin, et al.
Publicado: (2020)

UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer
por: Zhang, Nan, et al.
Publicado: (2022)

Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
por: Sun, Fengze, et al.
Publicado: (2022)

Advances in immunotherapy modalities for atherosclerosis
por: Meng, Qingwen, et al.
Publicado: (2023)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Advances in Drug Delivery via Biodegradable Ureteral Stent for the Treatment of Upper Tract Urothelial Carcinoma
por: Shan, Hongli, et al.
Publicado: (2020)

Comprehensive analyses of PDHA1 that serves as a predictive biomarker for immunotherapy response in cancer
por: Deng, Langmei, et al.
Publicado: (2022)

HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
por: Chen, Meiting, et al.
Publicado: (2023)

High mutations in fatty acid metabolism contribute to a better prognosis of small‐cell lung cancer patients treated with chemotherapy
por: Lyu, Qiong, et al.
Publicado: (2021)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
por: Shao, Rui, et al.
Publicado: (2019)

Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches
por: Bambury, Richard M., et al.
Publicado: (2013)

Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
por: Zhang, Yueming, et al.
Publicado: (2020)

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021)

Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma
por: Zheng, Yang, et al.
Publicado: (2023)

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma
por: Shibata, Yosuke, et al.
Publicado: (2023)

Identification of a lipid metabolism-related gene for cancer immunotherapy
por: Jiang, Xin, et al.
Publicado: (2023)

Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
por: Kitamura, Hiroshi, et al.
Publicado: (2011)

Immunotherapy in urothelial carcinoma: fade or future standard?
por: Breyer, Johannes, et al.
Publicado: (2016)

Ganoderma: A Cancer Immunotherapy Review
por: Cao, Yu, et al.
Publicado: (2018)

ORM Promotes Skeletal Muscle Glycogen Accumulation via CCR5-Activated AMPK Pathway in Mice
por: Qin, Zhen, et al.
Publicado: (2016)

The Relationship of Pyroptosis-Related Genes, Patient Outcomes, and Tumor-Infiltrating Cells in Bladder Urothelial Carcinoma (BLCA)
por: Xie, Ruiyan, et al.
Publicado: (2022)

Efficacy and Safety of Xueshuantong Injection on Acute Cerebral Infarction: Clinical Evidence and GRADE Assessment
por: Lyu, Jian, et al.
Publicado: (2020)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma
por: Liang, Fangfang, et al.
Publicado: (2021)

Clinical Efficacy Evaluation of 1-Year Subcutaneous Immunotherapy for Artemisia sieversiana Pollen Allergic Rhinitis by Serum Metabolomics
por: Shi, Hai-Yun, et al.
Publicado: (2020)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
por: Zhang, Ruihua, et al.
Publicado: (2022)

Efferocytosis signatures as prognostic markers for revealing immune landscape and predicting immunotherapy response in hepatocellular carcinoma
por: Xu, Ke, et al.
Publicado: (2023)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30t8q9d4p4t1vn1pio0uh45r43